Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Erika Serrano del Pozo
Observed names:
E. Serrano del Pozo,
E.S. del Pozo,
Erika Serrano Del pozo
Institution:
Vall d'Hebron Institute of Oncology
Observed institutions:
Universitat Autònoma de Barcelona,
Centre de Recerca en Sanitat Animal,
Vall d'Hebron Hospital Universitari,
Vall d'Hebron Institute of Oncology
ORCID:
0000-0003-2417-1499
Observed ORCID:
0000-0003-2417-1499
OpenAlex ID:
A5017078118
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
2019
·
Marie-Eve Beaulieu
, Toni Jauset
, et al.
·
Science Translational Medicine
·
224
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
2023
·
Mariano F. Zacarías-Fluck
, Daniel Massó-Vallés
, et al.
·
Genes & Development
·
22
PDF
Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue
2023
·
Marie-Eve Beaulieu
, Sandra Martínez-Martín
, et al.
·
Cancers
·
14
PDF
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets
2021
·
Mariano F Zacarías-Fluck
, Toni Jauset
, et al.
·
Life Science Alliance
·
11
PDF
False-Positive Results Obtained by Following a Commonly Used Reverse Transcription-PCR Protocol for Detection of Influenza A Virus
2006
·
Núria Busquets Martí
, Erika Serrano Del pozo
, et al.
·
Journal of Clinical Microbiology
·
8
Abstract 3435: Identification of potential biomarkers of response to OMO-103, a first-in-modality pan-MYC inhibitor, in patients with advanced solid tumors
2023
·
Marie-Eve Beaulieu
, Elena Garralda
, et al.
·
Cancer Research
·
1
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition
2022
·
Í. González-Larreategui
, L. Vera
, et al.
·
European Journal of Cancer
·
1
Abstract 7174: Restoring antitumor immunity and improving immunotherapy outcomes in KRAS-mutant NSCLC through MYC inhibition by OMO-103
2026
·
Íñigo González-Larreategui
, Sílvia Casacuberta-Serra
, et al.
·
Cancer Research
Corrigendum: Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
2025
·
Mariano F. Zacarías-Fluck
, Daniel Massó-Vallés
, et al.
·
Genes & Development
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC
2024
·
S. Casacuberta Serra
, I. González-Larreategui
, et al.
·
European Journal of Cancer
217 (PB205): Therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes
2024
·
I. González-Larreategui
, L. Vera
, et al.
·
European Journal of Cancer
IA16 A New Generation of Anti-Myc Mini-Proteins as Potential Therapy for NSCLC
2020
·
M.-E. Beaulieu
, T. Jauset
, et al.
·
Journal of Thoracic Oncology
Abstract 3956: Omomyc-based cell-penetrating peptides: From proof of concept to a clinically viable anti-Myc therapy
2018
·
Marie-Eve Beaulieu
, Toni Jauset
, et al.
·
Cancer Research
Abstract 2167: Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy
2017
·
Marie-eve Beaulieu
, Toni Jauset
, et al.
·
Cancer Research
Abstract B23: Pushing Myc inhibition towards the clinic by direct delivery of cell-penetrating peptides
2015
·
Marie-Eve Beaulieu
, Toni Jauset
, et al.
·
Molecular Cancer Research
El CReSA estudia millorar la detecció de virus en aus
2007
·
Núria Busquets
, Erika Serrano del Pozo
, et al.
·
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Show more works
View as search
Works count:
16
Citation count:
281
H-index:
5
I10-index:
4
Year
Topic
Type